Sirnaomics, Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Antisense, Oligonucleotides
    • Large Molecule

Other Names/Subsidiaries

  • Suzhou Sirnaomics Biopharmaceuticals Co. Ltd.
  • RNAimmune Inc.
  • Sirnaomics Ltd
See more in Biomedtracker

Latest on Sirnaomics, Inc.

Scrip

Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships

 
• By Dexter Jie Yan

Having successfully landed their anti-PD-1 Loqtorzi (toripalimab) in the US, Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. are set to jump-start a partnership bonanza for pot

Scrip

Deal Watch: Takeda Calls Upon The UK’s F-star Again For Bispecific Candidates

 
• By Joseph Haas and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda, F-star Sign Joint Research Pact

Scrip

Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat

 
• By Dexter Jie Yan

Six Chinese biotechs are reshuffling their research and development programs to conserve funds amid the persistent downturn in the sector, the companies disclosed in their annual results for 2022. Whi

Scrip

RNAi Developer Sirnaomics Targets Untapped Oncology Indications In China

 
• By Dexter Jie Yan

With no RNA interference-based therapy approved in China yet, Sirnaomics, Inc. is seeking to gain an edge over a growing number of local competitors by targeting cancer indications. With dual headqu